☆ 4.6 Article

Ruxolitinib as an Effective Treatment for Hemophagocytic Lymphohistiocytosis Secondary to SARS-Cov-2 Infection: A Case Report

INFECTION AND DRUG RESISTANCE (2023)

Related references

Note: Only part of the references are listed.

Review Medicine, Research & Experimental

Cytokine Storm Syndrome

Randy Q. Cron et al.

Summary: Cytokine storm syndrome (CSS) is a frequently fatal hyperinflammatory condition that has gained attention during the ongoing coronavirus pandemic. It encompasses various hyperinflammatory disorders associated with multiorgan system failure, including familial hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). Familial HLH is caused by genetic defects in the perforin pathway, while secondary HLH and MAS often involve NK cell dysfunction. Treatment for HLH involves targeting overactive lymphocytes and macrophages with etoposide and glucocorticoids, but more targeted and safer anticytokine approaches are becoming popular.

ANNUAL REVIEW OF MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Hemophagocytic Lymphohistiocytosis in Adults: A Retrospective Study in a Belgian Teaching Hospital

Halil Yildiz et al.

Summary: This study examined the clinical and biological characteristics of adult HLH patients in Belgium, revealing that malignancy and infection were the most common triggers. Risk factors for mortality included age, male sex, malignancy, and DIC, with age being the only significant factor in multivariate analysis.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2022)

Add to Collection

Article Immunology

Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS

Xiang Liu et al.

Summary: This study describes two cases of AIDS-related secondary HLH treated with ruxolitinib. The results highlight the feasibility of using ruxolitinib as a first-line therapy in patients with HIV infection and secondary HLH. However, the safety and efficacy of this novel treatment need to be evaluated in large clinical trials in the future.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Hematology

Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series

Sarah Hansen et al.

Summary: This case series demonstrates the effective use of JAK inhibition with ruxolitinib to control pathological immune activation in critically ill patients with secondary HLH, achieving good outcomes in patients with limited therapeutic options. JAK inhibition is also being urgently investigated for the treatment of cytokine storms associated with COVID-19.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Review Infectious Diseases

A case of Hemophagocytic lymphohistiocytosis induced by COVID-19, and review of all cases reported in the literature

Bircan Kayaaslan et al.

Summary: HLH secondary to COVID-19 can occur with high mortality rates, highlighting the importance of early diagnosis and treatment. Increasing awareness and prompt treatment for HLH triggered by COVID-19 can be lifesaving in reducing mortality rates among severe COVID-19 cases. It is essential to take timely treatment measures to prevent the occurrence and serious consequences of HLH in COVID-19 patients.

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2021)

Add to Collection

Article Medicine, General & Internal

Hemophagocytic lymphohistiocytosis in COVID-19 Case reports of a stepwise approach

Sebastian Schnaubelt et al.

Summary: The study reviewed three patients with COVID-19 who exhibited hyperinflammation and cytokine storm, requiring intensive care treatment. Diagnosis of secondary sHLH was made using HScore. A treatment regimen of methylprednisolone, pentaglobin, and anakinra was developed and administered. One patient survived while two others, diagnosed late, deceased.

MEDICINE (2021)

Add to Collection

Review Health Care Sciences & Services

Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies

Halil Yildiz et al.

Summary: Treatment of relapsed/refractory HLH in adults is mainly based on the HLH-94 regimen, but response rates are lower and some patients are refractory to this therapy. The development of new drugs provides new treatment options for patients. HSCT may be required for consolidation therapy in some cases.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2021)

Add to Collection

Article Infectious Diseases

Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report

Marco Meazza Prina et al.

Summary: This case report describes a woman diagnosed with sHLH related to previous Sars-CoV-2 infection and successfully treated with steroids, colchicine, etoposide, and ruxolitinib. It suggests that HLH-like syndrome might be secondary to Sars-CoV-2 infection even after complete recovery from mild symptoms. The treatment with low dose ruxolitinib plus etoposide could be a potential choice for Sars-CoV-2 infection related HLH.

BMC INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

New-onset IgG autoantibodies in hospitalized patients with COVID-19

Sarah Esther Chang et al.

Summary: In hospitalized COVID-19 patients, approximately 50% have detectable autoantibodies primarily targeting autoantigens associated with rare disorders. Additionally, a subset of autoantibodies develop de novo following SARS-CoV-2 infection.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Medicine, General & Internal

Systemic Lupus Erythematosus With Hemophagocytic Lymphohistiocytosis: Is COVID- 19 the Inciting Factor?

Ruhma Ali et al.

Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can lead to immune-mediated damage; Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition often accompanied by cytokine storm. HLH in the background of SLE is rare and potentially fatal.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

Add to Collection

Article Microbiology

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

George Dimopoulos et al.

CELL HOST & MICROBE (2020)

Add to Collection

Article Medicine, Research & Experimental

Clinical and immunological features of severe and moderate coronavirus disease 2019

Guang Chen et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Editorial Material Multidisciplinary Sciences

Cytokine release syndrome in severe COVID-19

John B. Moore et al.

SCIENCE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Bakiye Goker Bagca et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2020)

Add to Collection

Article Hematology

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

Paul La Rosee et al.

BLOOD (2019)

Add to Collection

Review Oncology

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities

Sattva S. Neelapu et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Hematology

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

Rupali Das et al.

BLOOD (2016)

Add to Collection

Review Hematology

Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review

Anna Hayden et al.

BLOOD REVIEWS (2016)

Add to Collection

Review Biochemistry & Molecular Biology

Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders

Ellen Brisse et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2015)

Add to Collection

Article Rheumatology

Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome

Laurence Fardet et al.

ARTHRITIS & RHEUMATOLOGY (2014)

Add to Collection

Review Hematology

Hemophagocytic lymphohistiocytosis: review of etiologies and management

Melissa R. George

JOURNAL OF BLOOD MEDICINE (2014)

Add to Collection

Review Medicine, Research & Experimental

Familial and Acquired Hemophagocytic Lymphohistiocytosis

G. E. Janka

ANNUAL REVIEW OF MEDICINE, VOL 63 (2012)

Add to Collection

Article Infectious Diseases

Infections associated with haemophagocytic syndrome

Nadine G. Rouphael et al.

LANCET INFECTIOUS DISEASES (2007)

Add to Collection

Review Oncology

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

Jan-Inge Henter et al.

PEDIATRIC BLOOD & CANCER (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.